Metabolomics

, Volume 10, Issue 1, pp 105–113 | Cite as

Spironolactone reduces aortic stiffness via blood pressure-dependent effects of canrenoate

  • Sonja B. Nikolic
  • Richard Wilson
  • James L. Hare
  • Murray J. Adams
  • Lindsay M. Edwards
  • James E. Sharman
Original Article

Abstract

Spironolactone is thought to improve aortic stiffness via blood pressure (BP) independent (antifibrotic) effects, but the exact mechanism is unknown. We used metabolomics and hemodynamic measures to reveal the underlying actions of spironolactone in people with a hypertensive response to exercise (HRE). Baseline and follow-up serum samples from 115 participants randomized to 3 months spironolactone (25 mg/day) or placebo were analysed using liquid chromatography/mass spectrometry and nuclear magnetic resonance spectroscopy. Hemodynamic measures recorded at baseline and follow-up included aortic pulse wave velocity (stiffness) and 24 h ambulatory BP. Aortic stiffness was significantly reduced by spironolactone compared with placebo (−0.18 ± 0.17 vs 0.30 ± 0.16 m/s; p < 0.05), but this was no longer significant after adjustment for the change in daytime systolic BP (p = 0.132). Further, the change in aortic stiffness was correlated with the change in daytime and 24 h systolic BP (p < 0.05). Metabolomics detected 42 features that were candidate downstream metabolites of spironolactone (no endogenous metabolites), although none were correlated with changes in aortic stiffness (p > 0.05 for all). However, the spironolactone metabolite canrenoate was associated with the change in daytime systolic BP (r = −0.355, p = 0.017) and 24 h pulse pressure (r = −0.332, p = 0.026). This remained highly significant on multiple regression and was independent of age, body mass index and sex. Canrenoate appears to be an active metabolite with BP-dependent effects on the attenuation of aortic stiffness in people with HRE. This finding, together with the lack of change in endogenous metabolites, suggests that the antifibrotic effects of spironolactone could be BP-dependent.

Keywords

Metabolomics Canrenone Canrenoate Hypertension Exercise 

References

  1. Benetos, A., Lacolley, P., & Safar, M. E. (1997). Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arteriosclerosis, Thrombosis, and Vascular Biology, 17(6), 1152–1156.CrossRefPubMedGoogle Scholar
  2. Brown, M., Wedge, D. C., Goodacre, R., et al. (2011). Automated workflows for accurate mass-based putative metabolite identification in LC/MS-derived metabolomic datasets. Bioinformatics, 27(8), 1108–1112. doi:10.1093/bioinformatics/btr079.CrossRefPubMedPubMedCentralGoogle Scholar
  3. Chobanian, A. V., Bakris, G. L., Black, H. R., et al. (2003). The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA, 289(19), 2560–2572. doi:10.1001/jama.289.19.2560.CrossRefPubMedGoogle Scholar
  4. De Meyer, T., Sinnaeve, D., Van Gasse, B., et al. (2008). NMR-based characterization of metabolic alterations in hypertension using an adaptive, intelligent binning algorithm. Analytical Chemistry, 80(10), 3783–3790. doi:10.1021/ac7025964.CrossRefPubMedGoogle Scholar
  5. Dieterle, F., Ross, A., Schlotterbeck, G., & Senn, H. (2006). Probabilistic quotient normalization as robust method to account for dilution of complex biological mixtures. Application in 1H NMR metabonomics. Analytical Chemistry, 78(13), 4281–4290. doi:10.1021/ac051632c.CrossRefPubMedGoogle Scholar
  6. Dunn, W. B., Broadhurst, D. I., Atherton, H. J., Goodacre, R., Griffin, J. L., et al. (2011a). Systems level studies of mammalian metabolomes: The roles of mass spectrometry and nuclear magnetic resonance spectroscopy. Chemical Society Reviews, 40(1), 387–426. doi:10.1039/b906712b.CrossRefPubMedGoogle Scholar
  7. Dunn, W. B., Broadhurst, D., Begley, P., et al. (2011b). Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nature Protocols, 6(7), 1060–1083. doi:10.1038/nprot.2011.335.CrossRefPubMedGoogle Scholar
  8. Edwards, L. M., Lawler, N. G., Nikolic, S. B., Peters, J. M., Horne, J., Wilson, R., et al. (2012). Metabolomics reveals increased isoleukotoxin diol (12,13-DHOME) in human plasma after acute Intralipid infusion. Journal of Lipid Research, 53(9), 1979–1986. doi:10.1194/jlr.P027706.CrossRefPubMedPubMedCentralGoogle Scholar
  9. Edwards, N. C., Steeds, R. P., Stewart, P. M., Ferro, C. J., & Townend, J. N. (2009). Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: A randomized controlled trial. Journal of the American College of Cardiology, 54(6), 505–512. doi:10.1016/j.jacc.2009.03.066.CrossRefPubMedGoogle Scholar
  10. Funder, J. W., Pearce, P. T., Smith, R., & Campbell, J. (1989). Vascular type I aldosterone binding sites are physiological mineralocorticoid receptors. Endocrinology, 125(4), 2224–2226.CrossRefPubMedGoogle Scholar
  11. Hare, J. L., Sharman, J. E., Leano, R., Jenkins, C., Wright, L., & Marwick, T. H. (2013). Impact of spironolactone on vascular, myocardial, and functional parameters in untreated patients with a hypertensive response to exercise. American Journal of Hypertension,. doi:10.1093/ajh/hpt008.PubMedGoogle Scholar
  12. Hatakeyama, H., Miyamori, I., Fujita, T., Takeda, Y., Takeda, R., & Yamamoto, H. (1994). Vascular aldosterone. Biosynthesis and a link to angiotensin II-induced hypertrophy of vascular smooth muscle cells. Journal of Biological Chemistry, 269(39), 24316–24320.PubMedGoogle Scholar
  13. Head, G. A., McGrath, B. P., Mihailidou, A. S., et al. (2012). Ambulatory blood pressure monitoring in Australia: 2011 consensus position statement. Journal of Hypertension, 30(2), 253–266. doi:10.1097/HJH.0b013e32834de621.CrossRefPubMedGoogle Scholar
  14. Holland, D. J., Sacre, J. W., McFarlane, S. J., Coombes, J. S., & Sharman, J. E. (2008). Pulse wave analysis is a reproducible technique for measuring central blood pressure during hemodynamic perturbations induced by exercise. American Journal of Hypertension, 21(10), 1100–1106. doi:10.1038/ajh.2008.253.CrossRefPubMedGoogle Scholar
  15. Lacolley, P., Safar, M. E., Lucet, B., Ledudal, K., Labat, C., & Benetos, A. (2001). Prevention of aortic and cardiac fibrosis by spironolactone in old normotensive rats. Journal of the American College of Cardiology, 37(2), 662–667.CrossRefPubMedGoogle Scholar
  16. Laurent, S., Cockcroft, J., Van Bortel, L., et al. (2006). Expert consensus document on arterial stiffness: Methodological issues and clinical applications. European Heart Journal, 27(21), 2588–2605. doi:10.1093/eurheartj/ehl254.CrossRefPubMedGoogle Scholar
  17. Lombes, M., Oblin, M. E., Gasc, J. M., Baulieu, E. E., Farman, N., & Bonvalet, J. P. (1992). Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circulation Research, 71(3), 503–510.CrossRefPubMedGoogle Scholar
  18. Mahmud, A., & Feely, J. (2005). Aldosterone-to-renin ratio, arterial stiffness, and the response to aldosterone antagonism in essential hypertension. American Journal of Hypertension, 18(1), 50–55. doi:10.1016/j.amjhyper.2004.08.026.CrossRefPubMedGoogle Scholar
  19. Mottram, P. M., Haluska, B., Leano, R., Cowley, D., Stowasser, M., & Marwick, T. H. (2004). Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation, 110(5), 558–565. doi:10.1161/01.cir.0000138680.89536.a9.CrossRefPubMedGoogle Scholar
  20. Mundal, R., Kjeldsen, S. E., Sandvik, L., Erikssen, G., Thaulow, E., & Erikssen, J. (1994). Exercise blood pressure predicts cardiovascular mortality in middle-aged men. Hypertension, 24(1), 56–62.CrossRefPubMedGoogle Scholar
  21. Overdiek, H. W., & Merkus, F. W. (1987). The metabolism and biopharmaceutics of spironolactone in man. Rev Drug Metab Drug Interact, 5(4), 273–302.CrossRefPubMedGoogle Scholar
  22. Palatini, P., Frigo, G., Bertolo, O., Roman, E., Da Corta, R., & Winnicki, M. (1998). Validation of the A&D TM-2430 device for ambulatory blood pressure monitoring and evaluation of performance according to subjects’ characteristics. Blood Press Monit, 3(4), 255–260.PubMedGoogle Scholar
  23. Pickering, T. G., Hall, J. E., Appel, L. J., et al. (2005). Recommendations for blood pressure measurement in humans and experimental animals: Part 1: Blood pressure measurement in humans: A statement for professionals from the Subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure Research. Circulation, 111(5), 697–716. doi:10.1161/01.CIR.0000154900.76284.F6.CrossRefPubMedGoogle Scholar
  24. Pitt, B., Zannad, F., Remme, W. J., et al. (1999). The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. New England Journal of Medicine, 341(10), 709–717. doi:10.1056/nejm199909023411001.CrossRefPubMedGoogle Scholar
  25. Sharman, J. E., Lim, R., Qasem, A. M., et al. (2006). Validation of a generalized transfer function to noninvasively derive central blood pressure during exercise. Hypertension, 47(6), 1203–1208.CrossRefPubMedGoogle Scholar
  26. Wehling, M. (2005). Effects of aldosterone and mineralocorticoid receptor blockade on intracellular electrolytes. Heart Failure Reviews, 10(1), 39–46. doi:10.1007/s10741-005-2347-z.CrossRefPubMedGoogle Scholar
  27. Wishart, D. S. (2008). Applications of metabolomics in drug discovery and development. Drugs R D, 9(5), 307–322.CrossRefPubMedGoogle Scholar
  28. Zannad, F., Alla, F., Dousset, B., Perez, A., & Pitt, B. (2000). Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation, 102(22), 2700–2706.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Sonja B. Nikolic
    • 1
  • Richard Wilson
    • 2
  • James L. Hare
    • 3
  • Murray J. Adams
    • 4
  • Lindsay M. Edwards
    • 5
  • James E. Sharman
    • 1
  1. 1.Menzies Research Institute TasmaniaUniversity of TasmaniaHobartAustralia
  2. 2.Central Science LaboratoryUniversity of TasmaniaHobartAustralia
  3. 3.Baker IDI Medical Research InstituteMelbourneAustralia
  4. 4.School of Human Life Sciences, University of TasmaniaLauncestonAustralia
  5. 5.Centre of Human and Aerospace Physiological SciencesKing’s College LondonLondonUK

Personalised recommendations